The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
Open accessPublished version of a preprint
Abstract
Abstract Background Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes an acute illness termed coronavirus disease 2019 (COVID-19). Humoral immune responses likely play an important role in containing SARS-CoV-2, however, the determinants of SARS-CoV-2-specific antibody responses are unclear. Methods Using immunoassays specific for the SARS-CoV-2 spike protein, we determined SARS-CoV-2-specific immunoglobulin A (IgA) and immunoglobulin G (IgG) in sera and mucosal fluids of two cohorts, including patients with quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR)-confirmed SARS-CoV-2 infection (n = 56; median age 61 years) with mild versus severe COVID-19, and SARS-CoV-2-exposed healthcare workers (n = 109; median age 36 years) with or without symptoms and tested negative or positive by RT-qPCR. Findings On average, SARS-CoV-2-specific serum IgA titers in mild COVID-19 cases became positive eight days after symptom onset and were often transient, whereas serum IgG levels remained negative or reached positive values 9–10 days after symptom onset. Conversely, patients with severe COVID-19 showed a highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers as a function of duration since symptom onset, independent of patient age and comorbidities. Very high levels of SARS-CoV-2-specific serum IgA correlated with severe acute respiratory distress syndrome (ARDS). Interestingly, some of the SARS-CoV-2-exposed healthcare workers with negative SARS-CoV-2-specific IgA and IgG serum titers had detectable SARS-CoV-2-specific IgA antibodies in their nasal fluids and tears. Moreover, SARS-CoV-2-specific IgA levels in nasal fluids of these healthcare workers were inversely correlated with patient age. Interpretation These data show that systemic IgA and IgG production against SARS-CoV-2 develops mainly in severe COVID-19, with very high IgA levels seen in patients with severe ARDS, whereas mild disease may be associated with transient serum titers of SARS-CoV-2-specific antibodies but stimulate mucosal SARS-CoV-2-specific IgA secretion. The findings suggest four grades of antibody responses dependent on COVID-19 severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
Viral dynamics in mild and severe cases of COVID-19
Liu, Y., Yan, L.-M., Wan, L., Xiang, T.-X., Le, A., Liu, J.-M., Peiris, M., Poon, L. L. M., & Zhang, W. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30232-2 · Cited by 1,727
Research works printed but not linked: 28
- 2020, The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat Microbiol, 5, 536, 10.1038/s41564-020-0695-z · DOI · Paper page
- Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270, 10.1038/s41586-020-2012-7 · DOI · Paper page
- V’kovski P, Gultom M, Steiner S, Kelly J, Russeil J, Mangeat B, et al. Disparate temperature-dependent virus – host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium [e-pub ahead of print]. bioRxiv http://biorxiv.org/lookup/doi/10.1101/2020.04.27.062315. Accessed November 27, 2020. · DOI
- Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility [e-pub ahead of print]. N Engl J Med https://doi.org/10.1056/NEJMoa2008457. Accessed November 27, 2020. · DOI · Paper page
- Tong, 2020, Potential presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2020, Emerg Infect Dis, 26, 1052, 10.3201/eid2605.200198 · DOI · Paper page
- Wu, 2020, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA, 323, 1239, 10.1001/jama.2020.2648 · DOI · Paper page
- Zhang, 2020, Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy, 75, 1730, 10.1111/all.14238 · DOI · Paper page
- Yang, 2020, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, 8, 475, 10.1016/S2213-2600(20)30079-5 · DOI · Paper page
- Ranieri, 2012, Acute respiratory distress syndrome: the Berlin definition, JAMA, 307, 2526
- To, 2020, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect Dis, 20, 565, 10.1016/S1473-3099(20)30196-1 · DOI · Paper page
- Ni, 2020, Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals, Immunity, 52, 971, 10.1016/j.immuni.2020.04.023 · DOI · Paper page
- Schulz, 2016, Viral evasion strategies in type I IFN signaling - a summary of recent developments, Front Immunol, 7, 498, 10.3389/fimmu.2016.00498 · DOI
- Hu, 2017, The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination, J Virol, 91, 10.1128/JVI.02143-16 · DOI · Paper page
- Blanco-Melo, 2020, Imbalanced host response to SARS-CoV-2 drives development of COVID-19, Cell, 181, 1036, 10.1016/j.cell.2020.04.026 · DOI · Paper page
- Amanna, 2010, Mechanisms that determine plasma cell lifespan and the duration of humoral immunity: long-term antibody production, Immunol Rev, 236, 125, 10.1111/j.1600-065X.2010.00912.x · DOI · Paper page
- Azkur, 2020, Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19, Allergy, 75, 1564, 10.1111/all.14364 · DOI · Paper page
- Bryant, 2020, Serology for SARS-CoV-2: apprehensions, opportunities, and the path forward, Sci Immunol, 5, 10.1126/sciimmunol.abc6347 · DOI
- Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 · DOI · Paper page
- Kaegi, 2019, Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders, Front Immunol, 10, 1990, 10.3389/fimmu.2019.01990 · DOI · Paper page
- Meyer, 2020, Validation of a commercially available SARS-CoV-2 serological immunoassay, Clin Microbiol Infect, 26, 1386, 10.1016/j.cmi.2020.06.024 · DOI
- Emmenegger M, De Cecco E, Lamparter D, Jacquat RPB, Ebner D, Schneider MM, et al. Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region [e-pub ahead of print]. medRxiv Available at: https://www.medrxiv.org/content/10.1101/2020.05.31.20118554v4. Accessed November 27, 2020. · doi:10.1101/2020.05.31.20118554v4
- Thissen, 2002, Quick and easy implementation of the Benjamini-Hochberg procedure for controlling the false positive rate in multiple comparisons, J Educ Behav Stat, 27, 77, 10.3102/10769986027001077 · DOI · Paper page
- Chan, 2009, Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus, J Clin Virol, 45, 54, 10.1016/j.jcv.2009.02.011 · DOI
- Liu, 2019, Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection, JCI Insight, 4, 10.1172/jci.insight.123158 · DOI · Paper page
- Yu, 2020, Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients, Eur Respir J, 56, 10.1183/13993003.01526-2020 · DOI · Paper page
- Shen, 2020, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA, 323, 1582, 10.1001/jama.2020.4783 · DOI · Paper page
- Chevrier S, Zurbuchen Y, Cervia C, Adamo S, Raeber ME, de Souza N, et al. A distinct innate immune signature marks progression from mild to severe COVID-19 [e-pub ahead of print]. bioRxiv Available at: http://biorxiv.org/lookup/doi/10.1101/2020.08.04.236315. Accessed November 27, 2020. · doi:10.1101/2020.08.04.236315
- Adamo S, Chevrier S, Cervia C, Zurbuchen Y, Raeber ME, Yang L, et al. Lymphopenia-induced T cell proliferation is a hallmark of severe COVID-19 [e-pub ahead of print]. bioRxiv Available at: http://biorxiv.org/lookup/doi/10.1101/2020.08.04.236521. Accessed November 27, 2020. · DOI
Cited by
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients
Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., Li, Z., Chao, G., Rojas, O. L., Bang, Y. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe5511 · Cited by 822
Infection fatality rate of COVID-19 inferred from seroprevalence data
Ioannidis, J. P. A. (2021) · Bulletin of the World Health Organization · doi:10.2471/blt.20.265892 · Cited by 684
The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review
Oran, D. P., & Topol, E. J. (2021) · Annals of Internal Medicine · doi:10.7326/m20-6976 · Cited by 533
Röltgen, K., Powell, A. E., Wirz, O. F., Stevens, B. A., Hogan, C. A., Najeeb, J., Hunter, M., Wang, H., Sahoo, M. K., Huang, C., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe0240 · Cited by 452
Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection
Russell, M. W., Moldoveanu, Z., Ogra, P. L., & Mestecky, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.611337 · Cited by 389
Metadata
- Authors
- Cervia, C., Nilsson, J., Zurbuchen, Y., Valaperti, A., Schreiner, J., Wolfensberger, A., Raeber, M. E., Adamo, S., Weigang, S., Emmenegger, M., Hasler, S., Bosshard, P. P., De Cecco, E., Bächli, E., Rudiger, A., Stüssi-Helbling, M., Huber, L. C., Zinkernagel, A. S., Schaer, D. J., Aguzzi, A., Kochs, G., Held, U., Probst-Müller, E., Rampini, S. K., & Boyman, O.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 147
- Issue
- 2
- Pages
- 545-557.e9
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W3098118792
- Cited by
- 408
- References
- 14
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Universität Zürich
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030-172978, 4078P0-198431)
- Universitätsspital Zürich
- Deutsches Zentrum für Luft- und Raumfahrt
- Bundesministerium für Bildung und Forschung (01KI2077)
- Schweizerische Akademie der Medizinischen Wissenschaften (YTCR 32/18, 323530-177975, 323530-191230, 323530-191220)
- Gottfried und Julia Bangerter-Rhyner-Stiftung
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. https://app.cochat.ai/papers/10.1016/j.jaci.2020.10.040
- The paper
- Cervia, C., Nilsson, J., Zurbuchen, Y., Valaperti, A., Schreiner, J., Wolfensberger, A., Raeber, M. E., Adamo, S., Weigang, S., Emmenegger, M., Hasler, S., Bosshard, P. P., De Cecco, E., Bächli, E., Rudiger, A., Stüssi-Helbling, M., Huber, L. C., Zinkernagel, A. S., Schaer, D. J., . . . Boyman, O. (2021). Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2020.10.040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
